Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/23/2026 | $12.00 | Buy | H.C. Wainwright |
| 5/8/2025 | $6.00 | Buy → Neutral | Chardan Capital Markets |
| 10/24/2024 | Neutral → Underweight | JP Morgan | |
| 6/26/2023 | $12.00 | Outperform | Oppenheimer |
| 4/21/2023 | $7.00 | Neutral | JP Morgan |
| 7/23/2021 | $42.00 → $29.00 | Buy | Canaccord Genuity |
| 7/23/2021 | $30.00 → $16.00 | Buy | Chardan Capital |
| 7/23/2021 | $36.00 → $18.00 | Outperform | Oppenheimer |
H.C. Wainwright initiated coverage of Seres Therapeutics with a rating of Buy and set a new price target of $12.00
Chardan Capital Markets downgraded Seres Therapeutics from Buy to Neutral and set a new price target of $6.00
JP Morgan downgraded Seres Therapeutics from Neutral to Underweight
CAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading live biotherapeutics company, today announced that it will host a webcast to discuss top-line results from an investigator-sponsored trial (IST) evaluating SER-155 in patients with immune checkpoint inhibitor-related enterocolitis, a serious and frequent side effect of immune checkpoint inhibitor cancer therapy. The IST was conducted at Memorial Sloan Kettering Cancer Center, with which Seres has a long history of collaboration, by Principal Investigator David Faleck, M.D., Director of Inflammatory and Immune-Related Bowel Diseases. The webcast will occur on July 8, 2026, at 8:30 am ET. T
Agreement with Nestlé Health Science provides $25 million payable to Seres in 2026 as a buy-out of potential future VOWST™ net sales-based milestones Restructured lease materially reduces ongoing annual facility cash costs and long-term lease liability Clinical data from investigator-sponsored SER-155 study in immune checkpoint inhibitor-related enterocolitis expected later this month CAMBRIDGE, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), ("Seres" or the "Company"), a leading live biotherapeutics company, today announced two transactions to strengthen its balance sheet and extend its expected operating cash runway well into the first quarter of 2027.
CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading live biotherapeutics company, today announced that management will attend the upcoming H.C. Wainwright 4th Annual BioConnect Investor Conference and will present a company overview at 3:30 p.m. ET on May 19, 2026. A live webcast of the presentation will be accessible through the "Events and Presentations" tab on the "Investors and News" section of the Company's website at http://www.serestherapeutics.com and will be available for replay following the event. About Seres TherapeuticsSeres Therapeutics, Inc. (NASDAQ:MCRB) is a clinical-stage biotechnology company developing novel live biothe
4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
4 - Seres Therapeutics, Inc. (0001609809) (Issuer)
8-K - Seres Therapeutics, Inc. (0001609809) (Filer)
8-K - Seres Therapeutics, Inc. (0001609809) (Filer)
10-Q - Seres Therapeutics, Inc. (0001609809) (Filer)
For Immediate Release: April 26, 2023 Today, the U.S. Food and Drug Administration approved Vowst, the first fecal microbiota product that is taken orally. Vowst is approved for the prevention of recurrence of Clostridioides difficile (C. difficile) infection (CDI) in individuals 18 years of age and older, following antibacterial treatment for recurrent CDI. “Today’s approval provides patients and healthcare p
CAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading live biotherapeutics company, today announced that it will host a webcast to discuss top-line results from an investigator-sponsored trial (IST) evaluating SER-155 in patients with immune checkpoint inhibitor-related enterocolitis, a serious and frequent side effect of immune checkpoint inhibitor cancer therapy. The IST was conducted at Memorial Sloan Kettering Cancer Center, with which Seres has a long history of collaboration, by Principal Investigator David Faleck, M.D., Director of Inflammatory and Immune-Related Bowel Diseases. The webcast will occur on July 8, 2026, at 8:30 am ET. T
Accomplished pharmaceutical executive brings extensive business development, licensing and finance experience Seres is implementing a focused corporate strategy to advance live biotherapeutic programs in inflammatory and immune diseases and support the readout of investigator-sponsored SER-155 study in immune checkpoint–related enterocolitis, a frequent and serious side effect in cancer patients treated with immune checkpoint inhibitors, expected in Q2 2026 SER-155 is Phase 2 ready for patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) to treat hematologic malignancies (cancers of the blood, bone marrow, and lymph nodes); efforts to secure funding for the program
Following constructive FDA feedback, Seres is finalizing its SER-155 Phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant for the treatment of hematological malignancies Efforts are ongoing to obtain capital and other resources to support SER-155 Phase 2 study; pending securing funding, interim clinical results anticipated within 12 months of study initiation Ongoing investigator-sponsored study in immune checkpoint related enterocolitis expected to inform broader SER-155 opportunity; initial study results anticipated in early 2026 Seres recently implemented actions to reduce operating costs; based on these
Readout of investigator-sponsored SER-155 study in immune checkpoint–related enterocolitis, a frequent and serious side effect in cancer patients treated with immune checkpoint inhibitors, on track for Q2 2026 Seres operational focus on advancing live biotherapeutic programs for inflammatory and immune diseases Company working to create meaningful partnerships with collaborators to support continued development of pipeline programs, including SER-155 for allogeneic hematopoietic stem cell transplant (allo-HSCT) CAMBRIDGE, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), (Seres or the Company), a leading live biotherapeutics company, today reported fou
Seres has finalized the protocol for the Phase 2 study of SER-155 in patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) with the FDA and has advanced key study startup activities and will pause further investment, while efforts to seek funding for the study remain ongoing Company's runway extension actions, including reducing the workforce by approximately 30%, are expected to extend its cash runway through Q3 2026 Seres will focus on advancing development of its early-stage live biotherapeutic programs in Inflammatory and immune diseases and supporting the read-out of clinical results from the fully enrolled Investigator-sponsored SER-155 study in immune checkp
Data demonstrate clinical translation of VOWST mechanisms of action in both first and multiply recurrent CDI patients Seres MbTx® platform provides high-resolution functional biological understanding of live biotherapeutics and supports the advancement of Seres' portfolio, including Phase 2-ready lead candidate SER-155 CAMBRIDGE, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading live biotherapeutics company, today announced the publication of two manuscripts in Nature Medicine and the Journal of Infectious Diseases highlighting new insights into the functional mechanism and clinical impact of VOWST™. Together, these publications provide further va
SC 13D/A - Seres Therapeutics, Inc. (0001609809) (Subject)
SC 13G/A - Seres Therapeutics, Inc. (0001609809) (Subject)
SC 13G/A - Seres Therapeutics, Inc. (0001609809) (Subject)